The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis ...

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...